Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24 2024 - 4:30PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced the appointment of Randy Teel, Ph.D.,
to the newly created role of Chief Business Officer. Dr. Teel
currently serves as Arvinas’ interim Chief Financial Officer and
Treasurer, and in his new role, he will remain a member of the
Executive Committee reporting to Chairperson, President and Chief
Executive Officer, John Houston, Ph.D. Dr. Teel will remain in
these interim roles at Arvinas while the board of directors
continues its search for a permanent Chief Financial Officer and
Treasurer.
"We are delighted to announce Randy's promotion to Chief
Business Officer,” said John Houston, Ph.D., Chairperson, President
and Chief Executive Officer at Arvinas. “Over his nearly six years
at Arvinas, Randy has demonstrated exceptional leadership. Since
our 2018 initial public offering, he has fostered strong
relationships with investors and partners alike. His dedication and
strategic vision have been instrumental in our growth, and we're
excited to see him drive our business forward in this new
role."
Dr. Teel has nearly 20 years of experience in the
biopharmaceutical industry. At Arvinas, in addition to finance, he
also leads corporate strategy, business development, investor
relations, and communications.
"I am incredibly excited to continue to advance our business in
this new role," said Dr. Teel. “Over the years, I've witnessed the
remarkable dedication and innovation at Arvinas, and I'm honored to
continue to contribute to our efforts as we bring new potential
therapies to patients. With a solid foundation laid and a dynamic
team in place, I look forward to working with our leadership and
employees to deliver exceptional value to our
stakeholders."About ArvinasArvinas is a
clinical-stage biotechnology company dedicated to improving the
lives of patients suffering from debilitating and life-threatening
diseases through the discovery, development, and commercialization
of therapies that degrade disease-causing proteins. Arvinas uses
its proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC protein degraders against validated
and “undruggable” targets, the company has four investigational
clinical-stage programs: vepdegestrant (ARV-471) for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer; ARV-766 and bavdegalutamide for the treatment of patients
with metastatic castration-resistant prostate cancer; and ARV-102
for the treatment of patients with neurodegenerative disorders. For
more information, visit www.arvinas.com.
Arvinas Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995 that involve substantial risks and
uncertainties, including statements regarding Arvinas’ ability to
bring its technology to patients and the potential therapeutic
benefits of the product candidates in Arvinas’ PROTAC® protein
degrader pipeline. The words “believe,” “expect,” “may,” “plan,”
“potential,” “will,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Arvinas
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on such forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements made as a result of various risks and uncertainties,
including but not limited to: Arvinas’ approach to the discovery
and development of product candidates based on its PROTAC
technology platform is unproven, which makes it difficult to
predict the time, cost of development and likelihood of
successfully developing any products; Arvinas’ ability to protect
its intellectual property position; whether cash and cash
equivalent resources will be sufficient to fund Arvinas’
foreseeable and unforeseeable operating expenses and capital
expenditure requirements; and other important factors discussed in
the “Risk Factors” section of the company’s Annual Report on Form
10-K for the year ended December 31, 2023, and subsequent other
reports on file with the U.S. Securities and Exchange Commission.
The forward-looking statements contained in this press release
reflect current views with respect to future events, and Arvinas
assumes no obligation to update any forward-looking statements
except as required by applicable law. These forward-looking
statements should not be relied upon as representing Arvinas’ views
as of any date after the date of this release.
Arvinas Contacts
Investor Contact:Jeff Boyle, Arvinas Investor
Relations+1 (347) 247-5089Jeff.Boyle@arvinas.com
Media Contact:Kathleen Murphy, Arvinas
Communications+1 (760) 622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2024 to May 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From May 2023 to May 2024